What is Pasithea Therapeutics' operating income?

Pasithea Therapeutics' total operating income in 2025 was -$20.86 million, based on the following breakdown: Total Gross Profit: $0.00 Total Operating Expenses: $20.86 million

Pasithea Therapeutics (KTTA) Financials

$0.45 -0.01 (-1.57%)

Closing price 07/17/2026 04:00 PM Eastern

Extended Trading

$0.45 0.00 (0.00%)

As of 07/17/2026 06:50 PM Eastern

Compare

Annual Income Statements for Pasithea Therapeutics

This table shows Pasithea Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2021	2022	2023	2024	2025
Period end date	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-2.17	-13	-16	-14	-20
Consolidated Net Income / (Loss)	-2.17	-14	-16	-14	-20
Net Income / (Loss) Continuing Operations	-2.17	-12	-16	-14	-20
Total Pre-Tax Income	-2.17	-12	-16	-14	-20
Total Operating Income	-4.51	-13	-16	-14	-21
Total Gross Profit	-0.00	0.00	0.00	0.00	0.00
Total Revenue	0.02	0.00	0.00	0.00	0.00
Total Cost of Revenue	0.02	0.00	0.00	0.00	0.00
Total Operating Expenses	4.51	13	16	14	21
Selling, General & Admin Expense	4.51	9.92	7.88	7.05	13
Research & Development Expense	0.00	2.67	8.10	7.20	7.98
Total Other Income / (Expense), net	2.33	1.72	0.47	0.35	0.44
Interest & Investment Income	-	-	0.42	0.42	0.33
Other Income / (Expense), net	2.33	1.71	0.06	-0.08	0.11
Income Tax Expense	0.00	0.00	0.00	0.00	0.00
Basic Earnings per Share	($0.21)	-	($13.01)	($12.69)	($2.91)
Weighted Average Basic Shares Outstanding	10.40M	1.26M	1.23M	1.10M	7.03M
Diluted Earnings per Share	-	-	($13.01)	($12.69)	($2.91)
Weighted Average Diluted Shares Outstanding	22.86M	26.13M	1.23M	1.10M	7.03M
Weighted Average Basic & Diluted Shares Outstanding	22.86M	26.13M	1.04M	2.71M	24.94M

This table shows Pasithea Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-3.61	-5.05	-3.86	-3.87	-3.03	-3.15	-3.56	-3.72	-3.04	-10	-2.87
Consolidated Net Income / (Loss)	-3.61	-5.05	-3.86	-3.87	-3.00	-3.18	-3.56	-3.72	-3.04	-10	-2.87
Net Income / (Loss) Continuing Operations	-3.61	-5.03	-3.86	-3.87	-3.00	-3.18	-3.56	-3.72	-3.04	-10	-2.87
Total Pre-Tax Income	-3.61	-5.03	-3.86	-3.87	-3.00	-3.18	-3.56	-3.72	-3.04	-10	-2.87
Total Operating Income	-3.79	-5.15	-4.04	-3.95	-3.00	-3.26	-3.68	-3.81	-3.11	-10	-4.88
Total Gross Profit	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Cost of Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Operating Expenses	3.79	5.15	4.04	3.95	3.00	3.26	3.68	3.81	3.11	10	4.88
Selling, General & Admin Expense	2.16	1.80	2.29	1.59	1.42	1.75	1.95	1.66	1.75	7.51	1.93
Research & Development Expense	1.62	3.35	1.75	2.36	1.58	1.51	1.73	2.15	1.36	2.74	2.94
Total Other Income / (Expense), net	0.18	0.12	0.18	0.08	0.01	0.08	0.12	0.09	0.07	0.15	2.01
Interest & Investment Income	0.13	-	0.15	0.11	0.08	0.08	0.05	0.05	0.04	0.18	0.45
Other Income / (Expense), net	0.04	-0.17	0.03	-0.04	-0.07	-0.00	0.08	0.04	0.03	-0.03	1.56
Income Tax Expense	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Basic Earnings per Share	-	($4.12)	($3.70)	($3.71)	($2.87)	($2.87)	($1.61)	($0.66)	($0.41)	($1.44)	($0.12)
Weighted Average Basic Shares Outstanding	1.26M	1.23M	1.04M	1.04M	1.04M	1.10M	2.21M	5.64M	7.44M	7.03M	24.34M
Diluted Earnings per Share	-	($4.12)	($3.70)	($3.71)	($2.87)	($2.87)	($1.61)	($0.66)	($0.41)	($1.44)	($0.12)
Weighted Average Diluted Shares Outstanding	1.26M	1.23M	1.04M	1.04M	1.04M	1.10M	2.21M	5.64M	7.44M	7.03M	24.34M
Weighted Average Basic & Diluted Shares Outstanding	20.84M	1.04M	1.04M	1.04M	1.27M	2.71M	7.44M	7.44M	7.44M	24.94M	33.41M

This table details how cash moves in and out of Pasithea Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2021	2022	2023	2024	2025
Period end date	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	105	-20	-17	-9.41	48
Net Cash From Operating Activities	-3.17	-12	-13	-14	-15
Net Cash From Continuing Operating Activities	50	-12	-13	-14	-15
Net Income / (Loss) Continuing Operations	-2.17	-12	-16	-14	-20
Consolidated Net Income / (Loss)	-2.17	-	-16	-14	-20
Depreciation Expense	0.00	0.01	0.02	0.02	0.03
Amortization Expense	0.00	0.00	0.63	0.63	0.63
Non-Cash Adjustments To Reconcile Net Income	1.22	-1.02	0.47	0.85	4.46
Changes in Operating Assets and Liabilities, net	50	0.85	1.57	-1.52	0.10
Net Cash From Investing Activities	-0.02	-2.30	0.40	0.00	0.01
Net Cash From Continuing Investing Activities	-0.02	-2.30	0.08	0.00	0.01
Sale of Property, Plant & Equipment	-	0.00	0.11	0.00	0.01
Net Cash From Financing Activities	56	-3.21	-3.73	4.52	64
Net Cash From Continuing Financing Activities	56	-3.21	-3.73	4.52	64
Repayment of Debt	-	0.00	-0.39	0.00	-0.45
Issuance of Common Equity	1.21	-	0.00	4.52	62
Other Financing Activities, net	28	-	0.00	0.00	2.25
Cash Interest Paid	-	-	-	0.00	0.01
Cash Income Taxes Paid	-	-	-	0.00	0.00

This table details how cash moves in and out of Pasithea Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	-7.06	-3.25	-4.32	-4.04	1.39	-2.44	-1.51	1.88	-2.99	51	-3.24
Net Cash From Operating Activities	-3.25	-3.31	-4.32	-4.04	-3.12	-2.44	-3.06	-3.87	-2.89	-5.40	-4.79
Net Cash From Continuing Operating Activities	-3.24	-3.29	-4.32	-4.04	-3.12	-2.44	-2.99	-3.87	-2.89	-5.40	-3.25
Net Income / (Loss) Continuing Operations	-3.61	-5.03	-3.86	-3.87	-3.00	-3.18	-3.56	-3.72	-3.04	-10	-2.87
Consolidated Net Income / (Loss)	-3.61	-5.03	-3.86	-3.87	-3.00	-3.18	-3.56	-3.72	-3.04	-10	-2.87
Depreciation Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.02	-	0.00
Amortization Expense	0.16	0.16	0.16	0.16	0.16	0.16	0.16	0.16	0.16	0.16	0.16
Non-Cash Adjustments To Reconcile Net Income	0.08	0.12	0.32	0.20	0.22	0.12	0.10	0.07	0.11	4.25	0.14
Changes in Operating Assets and Liabilities, net	0.13	1.45	-0.94	-0.53	-0.50	0.46	0.32	-0.38	-0.14	0.31	-0.67
Net Cash From Investing Activities	0.05	0.05	0.00	-	-	-	0.00	-	-	0.01	0.00
Net Cash From Continuing Investing Activities	0.05	0.05	0.00	-	-	-	0.00	-	-	0.01	0.00
Net Cash From Financing Activities	-3.86	-	0.00	-	4.54	-0.02	1.47	5.74	-0.12	56	0.00
Net Cash From Continuing Financing Activities	-3.86	-	0.00	-	4.54	-0.02	1.47	5.74	-0.12	56	0.00
Repayment of Debt	-0.13	-	0.00	-	-	-	-0.18	-0.11	-0.12	-0.04	0.00
Issuance of Common Equity	-	-	0.00	-	5.00	-0.48	1.65	4.57	0.00	55	0.00
Cash Interest Paid	-	-	0.00	-	-	-	0.01	0.01	-	-	0.01
Cash Income Taxes Paid	-	-	0.00	-	-	-	0.00	-	-	-	0.00

This table presents Pasithea Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	0.25	53	45	26	16	60
Total Current Assets	0.25	53	34	17	7.37	56
Cash & Equivalents	0.24	53	33	16	6.92	55
Restricted Cash	-	-	-	-	0.00	0.10
Prepaid Expenses	0.00	0.33	0.56	0.22	0.30	0.81
Other Current Assets	-	0.00	0.26	0.10	0.14	0.39
Plant, Property, & Equipment, net	0.00	0.02	0.13	0.14	0.12	0.00
Total Noncurrent Assets	0.00	0.00	11	9.28	8.57	3.78
Intangible Assets	-	0.00	8.57	7.94	7.31	3.78
Total Liabilities & Shareholders' Equity	0.25	53	45	26	16	60
Total Liabilities	0.01	1.90	2.68	2.72	1.28	5.02
Total Current Liabilities	0.01	0.45	1.88	2.63	1.12	4.97
Accounts Payable	0.01	0.45	1.48	2.55	1.12	1.13
Other Current Liabilities	-	0.00	0.16	0.08	-	3.84
Total Noncurrent Liabilities	0.00	1.45	0.80	0.08	0.16	0.05
Other Noncurrent Operating Liabilities	0.00	1.45	0.48	0.08	0.16	0.05
Total Equity & Noncontrolling Interests	0.24	51	42	23	15	55
Total Preferred & Common Equity	0.24	51	42	23	15	55
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	0.24	51	42	23	15	55
Common Stock	0.28	54	62	59	64	125
Retained Earnings	-0.04	-2.21	-19	-35	-50	-70
Accumulated Other Comprehensive Income / (Loss)	0.00	-0.01	-0.00	-0.00	-0.01	0.02

This table presents Pasithea Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	31	22	18	19	15	17	14	56
Total Current Assets	21	13	8.64	9.78	6.12	8.64	5.53	53
Cash & Equivalents	20	12	7.97	9.36	5.34	7.22	4.12	50
Restricted Cash	-	-	-	-	-	-	0.10	0.10
Prepaid Expenses	0.99	1.04	0.57	0.32	0.62	1.30	1.29	1.83
Other Current Assets	0.11	0.10	0.10	0.10	0.16	0.12	0.02	0.40
Plant, Property, & Equipment, net	0.15	0.14	0.13	0.13	0.12	0.11	0.00	0.00
Total Noncurrent Assets	9.74	9.08	8.89	8.73	8.42	8.26	8.10	3.62
Intangible Assets	8.10	7.78	7.63	7.47	7.15	7.00	6.84	3.62
Total Liabilities & Shareholders' Equity	31	22	18	19	15	17	14	56
Total Liabilities	2.28	2.52	1.49	0.82	1.68	1.83	1.42	1.54
Total Current Liabilities	2.04	2.47	1.39	0.66	1.59	1.74	1.38	1.49
Accounts Payable	1.87	2.43	1.39	0.66	1.33	1.58	1.34	1.49
Other Current Liabilities	0.17	0.03	0.00	0.00	0.27	0.16	0.04	0.00
Total Noncurrent Liabilities	0.24	0.06	0.09	0.16	0.09	0.09	0.05	0.05
Other Noncurrent Operating Liabilities	0.24	0.06	0.09	0.16	0.09	0.09	0.05	0.05
Total Equity & Noncontrolling Interests	28	20	16	18	13	15	12	55
Total Preferred & Common Equity	28	20	16	18	13	15	12	55
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	28	20	16	18	13	15	12	55
Common Stock	59	59	59	64	66	72	72	128
Retained Earnings	-30	-39	-43	-46	-53	-57	-60	-73
Accumulated Other Comprehensive Income / (Loss)	-0.01	-0.01	-0.01	-0.04	0.00	0.01	0.02	0.05

This table displays calculated financial ratios and metrics derived from Pasithea Therapeutics' official financial filings.

Metric	2021	2022	2023	2024	2025
Period end date	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	13,208,371.00	29,248,688.00	20,836,623.00	20,836,623.00	20,836,623.00
DEI Adjusted Shares Outstanding	660,419.00	1,462,434.00	1,041,831.00	1,041,831.00	1,041,831.00
DEI Earnings Per Adjusted Shares Outstanding	-3.29	-8.94	-15.32	-13.35	-19.61
Growth Metrics	-	-	-	-	-
Revenue Growth	0.00%	-100.00%	0.00%	0.00%	0.00%
EBITDA Growth	0.00%	-400.65%	-40.49%	10.45%	-46.83%
EBIT Growth	0.00%	-400.57%	-46.39%	10.02%	-44.81%
NOPAT Growth	0.00%	-179.29%	-26.93%	10.82%	-46.37%
Net Income Growth	0.00%	-541.19%	-14.53%	12.89%	-46.91%
EPS Growth	0.00%	0.00%	0.00%	2.46%	77.07%
Operating Cash Flow Growth	0.00%	-274.74%	-12.87%	-3.71%	-9.25%
Free Cash Flow Firm Growth	0.00%	0.00%	53.61%	-19.38%	38.01%
Invested Capital Growth	0.00%	692.35%	-23.28%	11.86%	-100.52%
Revenue Q/Q Growth	0.00%	-100.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	0.00%	-54.40%	-14.67%	13.04%	-53.82%
EBIT Q/Q Growth	0.00%	-54.43%	-15.29%	12.53%	-51.17%
NOPAT Q/Q Growth	0.00%	-19.87%	-7.44%	11.71%	-50.48%
Net Income Q/Q Growth	0.00%	-70.19%	0.43%	11.86%	-51.38%
EPS Q/Q Growth	0.00%	0.00%	0.43%	16.13%	-60.77%
Operating Cash Flow Q/Q Growth	0.00%	-3.61%	-9.39%	5.87%	-24.10%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	38.47%	2.24%	27.44%
Invested Capital Q/Q Growth	0.00%	108.61%	-19.17%	-7.01%	-100.51%
Profitability Metrics	-	-	-	-	-
Gross Margin	-14.69%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	-14,417.97%	0.00%	0.00%	0.00%	0.00%
Operating Margin	-29,925.73%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	-14,427.12%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	-14,430.49%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	100.00%	118.83%	102.93%	100.00%	100.00%
Interest Burden Percent	100.02%	107.82%	97.39%	97.05%	98.46%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-8.41%	-29.68%	-48.44%	-72.83%	-58.36%
Cash Return on Invested Capital (CROIC)	0.00%	-213.10%	-111.87%	-145.20%	0.00%
Operating Return on Assets (OROA)	-8.11%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	-8.11%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-8.41%	-29.68%	-48.44%	-72.83%	-58.36%
Return on Equity Simple (ROE_SIMPLE)	-4.23%	-32.79%	-68.22%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-3.16	-8.81	-11	-9.97	-15
NOPAT Margin	-20,948.01%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	1.85%	-11.87%	-19.22%	-33.74%	-18.74%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-47.80%	-67.48%	-26.44%
Cost of Revenue to Revenue	114.69%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	29,911.03%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	29,911.03%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-2.17	-11	-16	-14	-21
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-2.17	-11	-15	-14	-20
Valuation Ratios	-	-	-	-	-
Price to Book Value (P/BV)	0.79	7.89	0.39	0.23	0.16
Price to Tangible Book Value (P/TBV)	0.79	10.27	0.64	0.56	0.18
Price to Revenue (P/Rev)	2,686.18	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	33.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.03	-0.92	-0.75	-0.61	-0.89
Leverage Ratio	1.04	1.05	1.08	1.10	1.09
Compound Leverage Factor	1.04	1.13	1.05	1.07	1.07
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	13.77	74.48	-1.26	-5.18	-0.65
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-
Current Ratio	119.17	18.15	6.34	6.58	11.35
Quick Ratio	118.42	17.62	6.20	6.18	11.09
Cash Flow Metrics	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-20	-9.05	-11	-6.70
Operating Cash Flow to CapEx	-14,761.00%	-11,105.93%	0.00%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.08	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	4,795.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	-4,795.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-
Invested Capital	-1.55	9.16	7.03	7.86	-0.04
Invested Capital Turnover	-0.01	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	0.00	11	-2.13	0.83	-7.90
Enterprise Value (EV)	-13	302	-7.25	-3.47	-46
Market Capitalization	40	335	9.08	3.45	9.07
Book Value per Share	$3.89	$1.45	$1.12	$13.49	$7.85
Tangible Book Value per Share	$3.89	$1.12	$0.68	$5.66	$7.32
Total Capital	51	42	23	15	55
Total Debt	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00
Net Debt	-53	-33	-16	-6.92	-55
Capital Expenditures (CapEx)	0.02	0.11	-0.08	0.00	-0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-0.11	-0.89	-2.27	-0.67	-3.77
Debt-free Net Working Capital (DFNWC)	53	32	14	6.25	51
Net Working Capital (NWC)	53	32	14	6.25	51
Net Nonoperating Expense (NNE)	-0.98	5.12	4.78	3.93	5.83
Net Nonoperating Obligations (NNO)	-53	-33	-16	-6.92	-55
Total Depreciation and Amortization (D&A)	0.00	0.01	0.65	0.65	0.66
Debt-free, Cash-free Net Working Capital to Revenue	-753.74%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	350,904.11%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	350,904.11%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-
Adjusted Basic Earnings per Share	($4.20)	($11.00)	$0.00	($12.69)	($2.91)
Adjusted Weighted Average Basic Shares Outstanding	520.23K	1.26M	1.23M	1.10M	7.03M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00	($12.69)	($2.91)
Adjusted Weighted Average Diluted Shares Outstanding	1.14M	1.31M	1.04M	1.10M	7.03M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	1.14M	1.31M	1.04M	2.71M	24.94M
Normalized Net Operating Profit after Tax (NOPAT)	-3.16	-8.81	-11	-9.97	-15
Normalized NOPAT Margin	-20,948.01%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	-14,430.49%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	1,249.84%	-23.01%	-23.35%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Pasithea Therapeutics' official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	26,143,407.00	20,836,623.00	20,836,623.00	20,836,623.00	20,836,623.00	20,836,623.00	20,836,623.00	20,836,623.00	20,836,623.00	20,836,623.00	20,836,623.00
DEI Adjusted Shares Outstanding	1,307,170.00	1,041,831.00	1,041,831.00	1,041,831.00	1,041,831.00	1,041,831.00	1,041,831.00	1,041,831.00	1,041,831.00	1,041,831.00	1,041,831.00
DEI Earnings Per Adjusted Shares Outstanding	-2.76	-4.85	-3.71	-3.71	-2.91	-3.02	-3.42	-3.57	-2.92	-9.70	-2.75
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	14.53%	-61.08%	-24.09%	-11.13%	18.82%	39.82%	10.67%	5.49%	0.30%	-226.65%	8.10%
EBIT Growth	10.66%	-65.94%	-22.91%	-10.63%	18.01%	38.61%	10.23%	5.28%	-0.35%	-215.23%	7.87%
NOPAT Growth	1.72%	-27.36%	-25.78%	-3.04%	20.71%	36.69%	8.92%	3.40%	-3.51%	-214.65%	-32.51%
Net Income Growth	21.23%	1.36%	-9.13%	-2.74%	16.96%	37.05%	7.71%	3.88%	-1.25%	-218.19%	19.47%
EPS Growth	0.00%	1.36%	0.00%	0.00%	0.00%	30.34%	56.49%	82.21%	85.71%	49.83%	92.55%
Operating Cash Flow Growth	38.09%	-53.41%	-27.63%	-16.08%	3.96%	26.22%	29.28%	4.21%	7.38%	-120.91%	-56.66%
Free Cash Flow Firm Growth	37.78%	89.12%	88.79%	75.11%	73.24%	-111.59%	-78.17%	-20.12%	8.26%	123.15%	96.34%
Invested Capital Growth	98.01%	-23.28%	-16.01%	-8.33%	-2.78%	11.86%	-2.50%	-3.00%	-5.55%	-100.52%	-43.56%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	-4.26%	-43.85%	25.25%	0.87%	23.85%	-6.63%	-10.97%	-4.64%	19.66%	-249.34%	68.78%
EBIT Q/Q Growth	-4.06%	-41.95%	24.48%	0.83%	22.87%	-6.28%	-10.43%	-4.43%	18.29%	-233.87%	67.72%
NOPAT Q/Q Growth	1.03%	-35.88%	21.52%	2.37%	23.84%	-8.49%	-12.90%	-3.55%	18.39%	-229.77%	52.45%
Net Income Q/Q Growth	4.00%	-39.74%	23.52%	-0.14%	22.41%	-5.93%	-12.13%	-4.29%	18.26%	-232.88%	71.62%
EPS Q/Q Growth	0.00%	0.00%	10.19%	-0.27%	22.64%	0.00%	43.90%	59.01%	37.88%	-251.22%	91.67%
Operating Cash Flow Q/Q Growth	6.62%	-1.91%	-30.50%	6.53%	22.74%	21.71%	-25.08%	-26.61%	25.30%	-86.74%	11.30%
Free Cash Flow Firm Q/Q Growth	14.13%	78.84%	9.26%	-50.91%	7.65%	-67.32%	23.59%	-1.74%	29.47%	142.23%	-112.08%
Invested Capital Q/Q Growth	-2.90%	-19.17%	11.48%	4.78%	2.98%	-7.01%	-2.83%	4.24%	0.27%	-100.51%	10,726.82%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	100.00%	100.34%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	96.48%	94.66%	96.18%	97.13%	97.71%	97.39%	98.89%	98.56%	98.59%	98.30%	86.43%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-42.66%	-48.44%	-55.19%	-63.32%	-68.31%	-72.83%	-82.81%	-85.84%	-89.90%	-58.36%	-58.22%
Cash Return on Invested Capital (CROIC)	-224.92%	-111.87%	-119.73%	-129.37%	-128.96%	-145.20%	-123.15%	-116.05%	-112.36%	0.00%	-202.72%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-42.66%	-48.44%	-55.19%	-63.32%	-68.31%	-72.83%	-82.81%	-85.84%	-89.90%	-58.36%	-58.22%
Return on Equity Simple (ROE_SIMPLE)	-56.50%	0.00%	-81.90%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-2.65	-3.60	-2.83	-2.76	-2.10	-2.28	-2.58	-2.67	-2.18	-7.18	-3.41
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-3.09%	-5.81%	-4.93%	-6.38%	-6.17%	-7.69%	-11.35%	-13.81%	-12.67%	-9.43%	1.95%
Return On Investment Capital (ROIC_SIMPLE)	-	-15.40%	-14.23%	-17.07%	-11.81%	-15.43%	-19.85%	-17.58%	-17.83%	-13.00%	-6.23%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-3.74	-5.31	-4.01	-3.98	-3.07	-3.26	-3.60	-3.77	-3.08	-10	-3.32
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-3.58	-5.15	-3.85	-3.82	-2.91	-3.10	-3.44	-3.61	-2.90	-10	-3.16
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.43	0.39	0.38	0.33	0.32	0.23	0.22	0.27	0.45	0.16	0.33
Price to Tangible Book Value (P/TBV)	0.63	0.64	0.70	0.72	0.62	0.56	0.63	0.59	1.33	0.18	0.35
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.15	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.83	-0.75	-0.71	-0.67	-0.63	-0.61	-0.53	-0.48	-0.45	-0.89	-0.82
Leverage Ratio	1.07	1.08	1.09	1.08	1.07	1.10	1.13	1.11	1.07	1.09	1.05
Compound Leverage Factor	1.03	1.02	1.05	1.05	1.04	1.08	1.12	1.09	1.06	1.07	0.91
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	2.12	0.08	-0.67	-1.53	0.68	-2.91	-4.49	-3.59	-4.24	-0.08	6.11
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	10.16	6.34	5.35	6.20	14.81	6.58	3.84	4.97	4.02	11.35	35.40
Quick Ratio	9.63	6.20	4.87	5.71	14.18	6.18	3.35	4.16	2.99	11.09	33.84
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-6.96	-1.47	-1.34	-2.02	-1.86	-3.11	-2.38	-2.42	-1.71	0.72	-0.09
Operating Cash Flow to CapEx	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	8.69	7.03	7.83	8.21	8.45	7.86	7.64	7.96	7.98	-0.04	4.31
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	4.30	-2.13	-1.49	-0.75	-0.24	0.83	-0.20	-0.25	-0.47	-7.90	-3.33
Enterprise Value (EV)	-7.61	-7.25	-4.45	-2.69	-3.70	-3.47	-2.47	-3.15	1.22	-46	-32
Market Capitalization	12	9.08	7.56	5.28	5.66	3.45	2.87	4.07	5.45	9.07	18
Book Value per Share	$1.09	$1.12	$19.07	$15.50	$17.06	$13.49	$5.87	$2.69	$1.64	$7.85	$2.25
Tangible Book Value per Share	$0.73	$0.68	$10.40	$6.98	$8.70	$5.66	$2.06	$1.23	$0.55	$7.32	$2.10
Total Capital	28	23	20	16	18	15	13	15	12	55	55
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-20	-16	-12	-7.97	-9.36	-6.92	-5.34	-7.22	-4.22	-55	-51
Capital Expenditures (CapEx)	-0.05	-0.05	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-0.95	-2.27	-1.28	-0.72	-0.24	-0.67	-0.81	-0.32	-0.07	-3.77	0.74
Debt-free Net Working Capital (DFNWC)	19	14	11	7.25	9.12	6.25	4.53	6.90	4.15	51	51
Net Working Capital (NWC)	19	14	11	7.25	9.12	6.25	4.53	6.90	4.15	51	51
Net Nonoperating Expense (NNE)	0.96	1.44	1.03	1.10	0.90	0.90	0.99	1.05	0.86	2.93	-0.54
Net Nonoperating Obligations (NNO)	-20	-16	-12	-7.97	-9.36	-6.92	-5.34	-7.22	-4.22	-55	-51
Total Depreciation and Amortization (D&A)	0.16	0.16	0.16	0.16	0.16	0.16	0.16	0.16	0.18	0.16	0.16
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	($82.40)	$0.00	$0.00	($2.87)	($2.87)	($1.61)	($0.66)	($0.41)	($1.44)	($0.12)
Adjusted Weighted Average Basic Shares Outstanding	1.26M	61.33K	1.04M	1.04M	1.04M	1.10M	2.21M	5.64M	7.44M	7.03M	24.34M
Adjusted Diluted Earnings per Share	$0.00	($82.40)	$0.00	$0.00	($2.87)	($2.87)	($1.61)	($0.66)	($0.41)	($1.44)	($0.12)
Adjusted Weighted Average Diluted Shares Outstanding	1.04M	61.33K	1.04M	1.04M	1.04M	1.10M	2.21M	5.64M	7.44M	7.03M	24.34M
Adjusted Basic & Diluted Earnings per Share	$0.00	($82.40)	$0.00	$0.00	$0.00	($2.87)	$0.00	$0.00	$0.00	($1.44)	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	1.04M	52.12K	1.04M	1.04M	1.27M	2.71M	7.44M	7.44M	7.44M	24.94M	33.41M
Normalized Net Operating Profit after Tax (NOPAT)	-2.65	-3.60	-2.83	-2.76	-2.10	-2.28	-2.58	-2.67	-2.18	-7.18	-3.41
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-43.24%	-23.35%	0.00%	0.00%	-2.90%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Pasithea Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Pasithea Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Pasithea Therapeutics' net income appears to be on an upward trend, with a most recent value of -$20.43 million in 2025, rising from -$2.17 million in 2021. The previous period was -$13.90 million in 2024. Find out what analysts predict for Pasithea Therapeutics in the coming months.

Pasithea Therapeutics' total operating income in 2025 was -$20.86 million, based on the following breakdown:

Total Gross Profit: $0.00
Total Operating Expenses: $20.86 million

Over the last 4 years, Pasithea Therapeutics' total revenue changed from $15.06 thousand in 2021 to $0.00 in 2025, a change of -100.0%.

Pasithea Therapeutics' total liabilities were at $5.02 million at the end of 2025, a 291.6% increase from 2024, and a 75,938.6% increase since 2020.

In the past 5 years, Pasithea Therapeutics' cash and equivalents has ranged from $243.65 thousand in 2020 to $55.16 million in 2025, and is currently $55.16 million as of their latest financial filing in 2025.

Over the last 4 years, Pasithea Therapeutics' book value per share changed from 3.89 in 2021 to 7.85 in 2025, a change of 101.7%.

Related Companies

Financial statements for NASDAQ:KTTA last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pasithea Therapeutics (KTTA) Financials

Financials Breakdown Chart

Pasithea Therapeutics Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pasithea Therapeutics (KTTA) Financials

Annual Income Statements for Pasithea Therapeutics

Quarterly Income Statements for Pasithea Therapeutics

Annual Cash Flow Statements for Pasithea Therapeutics

Quarterly Cash Flow Statements for Pasithea Therapeutics

Annual Balance Sheets for Pasithea Therapeutics

Quarterly Balance Sheets for Pasithea Therapeutics

Annual Metrics And Ratios for Pasithea Therapeutics

Quarterly Metrics And Ratios for Pasithea Therapeutics

Financials Breakdown Chart

Pasithea Therapeutics Financials - Frequently Asked Questions

When does Pasithea Therapeutics' financial year end?

How has Pasithea Therapeutics' net income changed over the last 4 years?

What is Pasithea Therapeutics' operating income?

How has Pasithea Therapeutics' revenue changed over the last 4 years?

How much debt does Pasithea Therapeutics have?

How much cash does Pasithea Therapeutics have?

How has Pasithea Therapeutics' book value per share changed over the last 4 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools